<Record>
<Term>Olmesartan</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<ParentTerm>Angiotensin II Receptor Antagonist</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Adjuvant/Cardiovascular Agent/Antihypertensive Agent/Angiotensin II Receptor Antagonist/Olmesartan</ClassificationPath>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Cardiovascular Agent</BroaderTerm>
<BroaderTerm>Olmesartan</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Adjuvant</BroaderTerm>
<BroaderTerm>Angiotensin II Receptor Antagonist</BroaderTerm>
<BroaderTerm>Antihypertensive Agent</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<Synonym>OLMESARTAN</Synonym>
<Synonym>Olmesartan</Synonym>
<Description>A synthetic imidazole derivative and angiotensin II receptor antagonist with antihypertensive activity. Olmesartan selectively binds to the angiotensin type 1 (AT1) receptor subtype in vascular smooth muscle and adrenal gland, thereby competing with angiotensin II for binding to the AT1 receptor. This prevents angiotensin II-induced vasoconstriction and interferes with angiotensin II-mediated aldosterone secretion, thereby decreasing aldosterone production and preventing aldosterone-stimulated sodium retention and potassium excretion.</Description>
<Source>NCI Thesaurus</Source>
</Record>
